Tranexamic Acid After Pathological Fracture Treated With Modular Arthroplasty

Metastases to Bone Clinical Trial

Official title:
Tranexamic Acid After Pathological Fracture Treated With Modular Arthroplasty: Retrospective Observational Study

Status Completed

Clinical Trial Summary

This study assesses the safety and efficacy of TXA for patients treated for pathological femur fractures using modular prosthetics.

Clinical Trial Description

Tranexamic acid is an efficacious medication for curtailing blood loss, haemoglobin drop, and the requirement for transfusions. Additionally, it is a secure medication, even when administered to oncology patients receiving reduction haemarthroplasty for pathological femoral fractures. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06244498
Study type	Observational
Source	Podkarpackie Oncological Center
Contact
Status	Completed
Phase
Start date	January 1, 2018
Completion date	December 31, 2022

View Details

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT04170634` - Tumoral Bone Strength Assessment by Numerical Simulation Using Quantitative CT : the MEKANOS Study
	Withdrawn	`NCT03134404` - Project to Assess Feasibility of a Rapid Access Metastatic Bone Disease Program